Prostate Specific Antigen Test Articles & Analysis: Older
3 news found
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received FDA Breakthrough Device Designation for the IsoPSA® Assay, a novel prostate cancer diagnostic test. Published studies from multicenter prospective clinical trials ...
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary ...
Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics for the detection of cancers, today announced the online publication of interim results for an ongoing multi-center trial of the IsoPSA™ prostate cancer test in European Urology. The findings illustrate a significantly improved diagnostic accuracy over the ...